1.	Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: ICC2302, P30CA043703, CASE-CWRU-ICC-2302, CASE-2302, NCT00060242
2.	Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA4P-212, HCI-13214, NCT00113438
3.	A Study to Assess the Effectiveness of the Combination of Carboplatin, Paclitaxel, Bevacizumab and Combretastatin (CA4P) in Patients With Chemotherapy Naïve Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OXC401-216, NCT00653939
4.	Phase I Study of Combretastatin A4 Phosphate in Patients with Solid Tumors Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Protocol IDs: CRC-PHASE-I/II-PH1/066, EU-98066, NCT00003698
5.	Phase I Study of Combretastatin A4 Phosphate in Patients With Advanced Solid Tumors (Summary Last Modified 05/2001) Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: CWRU-ILEX-1Y98, ILEX-1Y98, ILEX-CA4P101-A3, NCI-G99-1502, NCT00003768
6.	Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OXC4P1-105, NCT00395434